Elevated activities of MMP‐2 in the non‐tumorous lung tissues of curatively resected stage I NSCLC patients are associated with tumor recurrence and a poor survival
- 26 February 2007
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 95 (4) , 337-346
Abstract
Background and Objectives We wanted to assess whether the level of enzyme activity for a particular matrix metalloproteinase (MMP), and not the amount of expressed protein, in lung tissue could be used as a reliable prognostic biomarker for tumor recurrence leading to poorer survival in a certain subgroup of patients who have undergone curative resection for stage I human NSCLC. Methods We determined what type of MMP was significant for tumor recurrence by using a mouse model of pulmonary metastasis with inoculating the footpad with H460 human cancer cells. We then looked for any association between tumor recurrence and the level of enzyme activities for the selected MMP in the tumor and also in the pathologically non‐tumorous tissues from 34 stage I lung cancer patients. Results We obtained H460/PM6 cells having a highly metastatic potential after six repeated cycles of pulmonary metastasis by using the mouse footpad inoculated with the metastasized cancer cells in the previous cycle. We started with human lung cancer cells, H460, and we found that among the tested MMPs we tested for, the level of MMP‐2 mRNA was elevated. No significant difference was seen in the level of enzyme activity of the MMP‐2 cells from the curatively resected tumor tissues of the stage I NSCLC patients who were later found with or without recurrence. However, the level of MMP‐2 enzyme activity was found to be significantly different between the non‐tumorous lung tissues from patients later found with and without recurrence, and it was associated with the 5‐year survival rate. Conclusions This observation suggests that the higher level of MMP‐2 enzyme activity in the non‐tumorous tissues from the patients could be used as a prognostic biomarker to predict post‐operative tumor recurrence and survival for patients with stage I NSCLC. The elevated enzyme activity of MMP‐2 in the non‐tumorous tissue resected from stage I NSCLC could be used as a prognostic indicator for post‐operative tumor recurrence and the patients' poor survival. Further, this could be an important aid for physicians' making decision on whether to subject particular patients to post‐operative adjunct chemotherapy. J. Surg. Oncol. 2007;95:337–346.Keywords
This publication has 26 references indexed in Scilit:
- Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-βJournal of Cell Science, 2005
- Matrix Metalloproteinase-2 Status in Stromal Fibroblasts, Not in Tumor Cells, Is a Significant Prognostic Factor in Non–Small-Cell Lung CancerClinical Cancer Research, 2004
- Extracellular matrix remodelling: the role of matrix metalloproteinasesThe Journal of Pathology, 2003
- In Vivo Localization of Gelatinases (MMP-2 and -9) by in Situ Zymography with a Selective Gelatinase InhibitorBiochemical and Biophysical Research Communications, 2001
- MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αvβ3 Promotes Maturation of MMP-2 in Breast Carcinoma CellsExperimental Cell Research, 2001
- Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancerRespiratory Medicine, 2001
- Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase aInternational Journal of Cancer, 1995
- Activation of the precursor of gelatinase A/72 kda type IV collagenase/MMP‐2 in lung carcinomas correlates with the expression of membrane‐type matrix metalloproteinase (MT‐MMP) and with lymph node metastasisInternational Journal of Cancer, 1995
- Recent Cancer Trends in the United StatesJNCI: Journal of the National Cancer Institute, 1995
- Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factorArchives of Biochemistry and Biophysics, 1991